Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (18517)	4/2/1998 1:49:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Tuck, LGND has indicated that elevated triglycerides can be a side effect at the highest doses used to treat CTCL (from the press release of Targretin oral treatment of CTCL): "Although a number of the higher dose patients have required dose modifications for related side effects, Targretin Capsules have been reasonably well-tolerated in the study population," according to Richard Yocum, MD, Medical Director of Clinical Research at Ligand. "The majority of the higher dose drug-related adverse events consisted of reversible neutropenia (a reduction of white blood cells) without infectious complications and elevation of serum triglycerides," Dr. Yocum said." The press release was somewhat abiguous, but IR did confirm that the "without" refered only to the infectious complications and some patients did have elevated triglycerides, a complication seen in retinoid therapies of others. I have no data on diabetic patients. The European study was designed to test several concentrations of Targretin. I believe that most or all of the concentrations used in the European diabetes trial were below the "higher dose" patients treated in the CTCL study. As noted recently and previously, the animal data (on animals that have elevated triglycerides), demonstrates a lowering of triglycerides in animals treated with Targretin.